We are excited to announce that the repository will soon undergo an upgrade, featuring a new look and feel along with several enhanced features to improve your experience. Please be on the lookout for further updates and announcements regarding the launch date. We appreciate your support and look forward to unveiling the improved platform soon.
dc.contributor.author | Sathekge, Mike Machaba![]() |
|
dc.contributor.author | Lengana, Thabo![]() |
|
dc.contributor.author | Modiselle, Moshe![]() |
|
dc.contributor.author | Vorster, Mariza![]() |
|
dc.contributor.author | Zeevaart, Jan Rijn![]() |
|
dc.contributor.author | Maes, Alex![]() |
|
dc.contributor.author | Ebenhan, Thomas![]() |
|
dc.contributor.author | Van de Wiele, Christophe![]() |
|
dc.date.accessioned | 2018-01-12T06:42:49Z | |
dc.date.available | 2018-01-12T06:42:49Z | |
dc.date.issued | 2017-04 | |
dc.description.abstract | BACKGROUND : To report on imaging findings using 68Ga-PSMAHBED- CC PET in a series of 19 breast carcinoma patients. METHODS : 68Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status. RESULTS : Out of 81 tumor lesions identified, 84% were identified on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptornegative lesions. SUV values derived from FDG PET/CT, available in seven patients, and 68Ga-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p= 0.015). CONCLUSIONS : 68Ga-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry. | en_ZA |
dc.description.department | Nuclear Medicine | en_ZA |
dc.description.librarian | am2018 | en_ZA |
dc.description.sponsorship | Department of Nuclear Medicine at University Pretoria and NECSA. | en_ZA |
dc.description.uri | https://link.springer.com/journal/259 | en_ZA |
dc.identifier.citation | Sathekge, M., Lengana, T., Modiselle, M. et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. European Journal of Nuclear Medicine and Molecular Imaging (2017) 44: 689-694. https://doi.org/10.1007/s00259-016-3563-6. | en_ZA |
dc.identifier.issn | 1619-7070 (print) | |
dc.identifier.issn | 1619-7089 (online) | |
dc.identifier.other | 10.1007/s00259-016-3563-6 | |
dc.identifier.uri | http://hdl.handle.net/2263/63510 | |
dc.language.iso | en | en_ZA |
dc.publisher | Springer | en_ZA |
dc.rights | © The Author(s) 2016. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/). | en_ZA |
dc.subject | 68Ga-PSMA | en_ZA |
dc.subject | PET/CT | en_ZA |
dc.subject | Breast cancer | en_ZA |
dc.subject | Prostate-specific membrane antigen (PSMA) | en_ZA |
dc.subject | Positron emission tomography (PET) | en_ZA |
dc.title | 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients | en_ZA |
dc.type | Article | en_ZA |